查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
欧洲药物动力学服务市场预测至 2031 年 - 区域分析 - 按药物类型、服务类型、治疗应用和最终用户
市场调查报告书
商品编码
1597065

欧洲药物动力学服务市场预测至 2031 年 - 区域分析 - 按药物类型、服务类型、治疗应用和最终用户

Europe Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type, Service Type, Therapeutic Application, and End User
出版日期: | 出版商: The Insight Partners | 英文 87 Pages | 订单完成后即时交付

价格

2023年欧洲药物动力学服务市值为2.2216亿美元，预计2031年将达到3.8738亿美元；预计2023年至2031年复合年增长率为7.2%。

将药物动力学服务外包给 CRO 推动欧洲药物动力学服务市场

将药物动力学服务外包给合约研究组织 (CRO) 为药厂和申办者提供了多种优势。他们可以透过选择这些服务来实现经济高效的营运。此外，他们可以专注于灵活工作并为其核心营运带来可扩展性，同时实现快速週转时间。外包帮助製药公司专注于产品商业化，同时实施能力建构、降低成本和资料管理等措施。药物发现过程很复杂，任何错误或错误结果都可能导致巨大的成本并延迟该过程。 CRO 聘用经验丰富的科学家和研究人员，他们在药物动力学和其他领域拥有专业知识。因此，它们为製药公司提供了获得其专业知识的机会，从而消除了投资僱用此类熟练劳动力或提供额外培训来培养他们的需要。因此，拥有有前景的候选药物但资源有限的小型公司和参与多角化经营的大公司都选择由组织良好的CRO提供的临床研究服务，这支持了欧洲药物动力学服务市场。

欧洲药物动力学服务市场概况

欧洲药物动力学服务市场分为德国、法国、英国、西班牙、义大利和欧洲其他地区。德国和义大利等国家预计将占据该地区市场的重要份额，法国、英国和西班牙等国家可能在药物动力学服务方面拥有成长机会。随着新药开发临床试验数量的增加，以及越来越多地采用体内和体外模型来了解药物动力学变异性，欧洲药物动力学服务市场预计在未来几年将会成长。

欧洲药物动力学服务市场收入及 2031 年预测（百万美元）

欧洲药物动力学服务市场细分

欧洲药物动力学服务市场分为药物类型、服务类型、治疗应用、最终用户和国家。

根据药物类型，欧洲药物动力学服务市场分为小分子、大分子和疫苗。 2023 年，小分子细分市场占据最大的市场份额。

从服务类型来看，欧洲药物动力学服务市场分为临床前ADME和人体研究、PK/PD分析和报告、给药模拟、风险分析等。 2023 年，临床前 ADME 和人体研究领域占据最大的市场份额。

依治疗应用，欧洲药物动力学服务市场分为肿瘤学、传染病、神经系统疾病、自体免疫疾病、妇科疾病、心血管疾病、呼吸系统疾病等。 2023 年，肿瘤学领域占据最大的市场份额。

依最终用户划分，欧洲药物动力学服务市场分为製药和生物技术公司、合约研究组织等。 2023 年，合约研究组织细分市场占据最大的市场份额。

依国家/地区划分，欧洲药物动力学服务市场分为德国、法国、英国、义大利、西班牙和欧洲其他地区。 2023 年，法国在欧洲药物动力学服务市场份额中占据主导地位。

查尔斯河实验室国际公司； Eurofins Scientific SE； Evotec SE；塞塔拉公司； Parexel国际公司；赛默飞世尔科技公司；艾伦特；太平洋生物实验室；和 SGS SA 是欧洲药物动力学服务市场上的一些领先公司。

目录

第 1 章：简介

第 2 章：执行摘要

  • 主要见解

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：欧洲药物动力学服务市场 - 主要市场动态

  • 市场驱动因素
    • 慢性病和传染病的盛行率上升
    • 扩大药物动力学研究的应用范围
    • 将药物动力学服务外包给 CRO
  • 市场限制
    • 新兴国家药物动力学服务提供者的覆盖范围有限
  • 市场机会
    • 越来越多地采用体内和体外模型来了解药物动力学的变异性
  • 未来趋势
    • 药物动力学服务中越来越多采用大数据分析
  • 驱动因素和限制的影响：

第 5 章：药物动力学服务市场 - 欧洲分析

  • 欧洲药物动力学服务市场收入，2021-2031

第 6 章：欧洲药物动力学服务市场分析 - 按药物类型

  • 概述
  • 小分子
  • 大分子
  • 疫苗

第 7 章：欧洲药物动力学服务市场分析 - 按服务类型

  • 概述
  • 临床前 ADME 和人体研究
  • PK/PD 分析和报告
  • 剂量模拟
  • 风险分析
  • 其他的

第 8 章：欧洲药物动力学服务市场分析 - 按治疗应用

  • 肿瘤学
  • 传染病
  • 神经系统疾病
  • 自体免疫疾病
  • 妇科疾病
  • 心血管疾病
  • 呼吸系统疾病
  • 其他的

第 9 章：欧洲药物动力学服务市场分析 - 按最终用户

  • 製药和生物技术公司
  • 合约研究组织
  • 其他的

第 10 章：欧洲药物动力学服务市场 - 国家分析

  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其余的

第 11 章：公司简介

  • Charles River Laboratories International Inc
  • Eurofins Scientific SE
  • Evotec SE
  • Certara Inc.
  • Parexel International Corp
  • Thermo Fisher Scientific Inc.
  • Allucent
  • PACIFIC BIOLABS
  • SGS SA

第 12 章：附录

Product Code: BMIRE00030902

The Europe pharmacokinetics services market was valued at US$ 222.16 million in 2023 and is expected to reach US$ 387.38 million by 2031; it is estimated to register a CAGR of 7.2% from 2023 to 2031.

Outsourcing of Pharmacokinetics Services to CROs Drives Europe Pharmacokinetics Services Market

Outsourcing pharmacokinetics services to contract research organizations (CROs) offers several advantages to drug manufacturers and sponsors. They can operate cost-effectively by opting for these services. Moreover, they can focus on working flexibly and bringing scalability to their core operations, alongside achieving fast turnaround time. Outsourcing helps pharmaceutical companies to focus on product commercialization while implementing measures for capacity building, cost reduction, and data management. The drug discovery process is complex, and any error or false result can lead to significant costs and delay the process. CROs employ experienced scientists and researchers who hold expertise in pharmacokinetics and other fields. Thus, they provide pharma companies with access to their expertise, thereby eliminating the need to invest in hiring such skilled workforces or providing extra training to build them. Therefore, small companies with promising drug candidates but limited resources and large companies involved in diversifying their operations are opting for clinical research services provided by well-organized CROs, which bolsters the Europe pharmacokinetics services market.

Europe Pharmacokinetics Services Market Overview

The Europe pharmacokinetics services market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Countries such as Germany and Italy are expected to account significant contributors share of the market in the region, and countries such as France, the UK, and Spain are likely to have growth opportunities for pharmacokinetics services. The European pharmacokinetics services market is expected to grow in the coming years with the rising number of clinical trials for new drug development, and the increasing adoption of in-vivo and in-vitro models for understanding pharmacokinetics variability.

Europe Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)

Europe Pharmacokinetics Services Market Segmentation

The Europe pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.

Based on drug type, the Europe pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.

In terms of service type, the Europe pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.

By therapeutic application, the Europe pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.

By end user, the Europe pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.

By country, the Europe pharmacokinetics services market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. France dominated the Europe pharmacokinetics services market share in 2023.

Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA are some of the leading companies operating in the Europe pharmacokinetics services market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Pharmacokinetics Services Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Prevalence of Chronic and Infectious Diseases
    • 4.1.2 Expanding Range of Application of Pharmacokinetic Studies
    • 4.1.3 Outsourcing of Pharmacokinetics Services to CROs
  • 4.2 Market Restraints
    • 4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
  • 4.3 Market Opportunities
    • 4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
  • 4.4 Future Trend
    • 4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
  • 4.5 Impact of Drivers and Restraints:

5. Pharmacokinetics Services Market - Europe Analysis

  • 5.1 Europe Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

6. Europe Pharmacokinetics Services Market Analysis - by Drug Type

  • 6.1 Overview
  • 6.2 Small Molecule
    • 6.2.1 Overview
    • 6.2.2 Small Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Large Molecule
    • 6.3.1 Overview
    • 6.3.2 Large Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.4 Vaccines
    • 6.4.1 Overview
    • 6.4.2 Vaccines: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7. Europe Pharmacokinetics Services Market Analysis - by Service Type

  • 7.1 Overview
  • 7.2 Pre-Clinical ADME and Human Studies
    • 7.2.1 Overview
    • 7.2.2 Pre-Clinical ADME and Human Studies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 PK/PD Analysis and Reporting
    • 7.3.1 Overview
    • 7.3.2 PK/PD Analysis and Reporting: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Dosing Simulations
    • 7.4.1 Overview
    • 7.4.2 Dosing Simulations: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Risk Analysis
    • 7.5.1 Overview
    • 7.5.2 Risk Analysis: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Pharmacokinetics Services Market Analysis - by Therapeutic Application

  • 8.1 Oncology
    • 8.1.1 Overview
    • 8.1.2 Oncology: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Infectious Diseases
    • 8.2.1 Overview
    • 8.2.2 Infectious Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Neurological Disorders
    • 8.3.1 Overview
    • 8.3.2 Neurological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Autoimmune Diseases
    • 8.4.1 Overview
    • 8.4.2 Autoimmune Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Gynecological Disorders
    • 8.5.1 Overview
    • 8.5.2 Gynecological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Cardiovascular Diseases
    • 8.6.1 Overview
    • 8.6.2 Cardiovascular Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.7 Respiratory Disorders
    • 8.7.1 Overview
    • 8.7.2 Respiratory Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.8 Others
    • 8.8.1 Overview
    • 8.8.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Pharmacokinetics Services Market Analysis - by End User

  • 9.1 Pharmaceutical and Biotechnology Companies
    • 9.1.1 Overview
    • 9.1.2 Pharmaceutical and Biotechnology Companies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Contract Research Organization
    • 9.2.1 Overview
    • 9.2.2 Contract Research Organization: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Others
    • 9.3.1 Overview
    • 9.3.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. Europe Pharmacokinetics Services Market - Country Analysis

  • 10.1 Europe
    • 10.1.1 Europe Pharmacokinetics Services Market Breakdown by Countries, 2023 and 2031 (%)
      • 10.1.1.1 Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.1.1 Overview
        • 10.1.1.1.2 Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.1.3 Germany: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.1.4 Germany: Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.1.5 Germany: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.1.6 Germany: Europe Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.2 France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.2.1 Overview
        • 10.1.1.2.2 France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.2.3 France: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.2.4 France: Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.2.5 France: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.2.6 France: Europe Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.3 United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.3.1 Overview
        • 10.1.1.3.2 United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.3.3 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.3.4 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.3.5 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.3.6 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.4 Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.4.1 Overview
        • 10.1.1.4.2 Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.4.3 Italy: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.4.4 Italy: Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.4.5 Italy: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.4.6 Italy: Europe Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.5 Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.5.1 Overview
        • 10.1.1.5.2 Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.5.3 Spain: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.5.4 Spain: Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.5.5 Spain: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.5.6 Spain: Europe Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.6 Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.6.1 Overview
        • 10.1.1.6.2 Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.6.3 Rest of Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.6.4 Rest of Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.6.5 Rest of Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.6.6 Rest of Europe Pharmacokinetics Services Market Breakdown, by End User

11. Company Profile

  • 11.1 Charles River Laboratories International Inc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Eurofins Scientific SE
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Evotec SE
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Certara Inc.
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
  • 11.5 Parexel International Corp
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Thermo Fisher Scientific Inc.
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Allucent
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 PACIFIC BIOLABS
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 SGS SA
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms for Pharmacokinetic Services Market

List Of Tables

  • Table 1. Europe Pharmacokinetics Services Market Segmentation
  • Table 2. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 3. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 4. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 5. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 6. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 7. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 8. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 9. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 10. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 11. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 12. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 13. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 14. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 15. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 16. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 17. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 18. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 19. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 20. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 21. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 22. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 23. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 24. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 25. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 26. Glossary of Terms

List Of Figures

  • Figure 1. Europe Pharmacokinetics Services Market Segmentation, by Country
  • Figure 2. Europe Pharmacokinetics Services Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
  • Figure 5. Europe Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
  • Figure 6. Small Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Large Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Vaccines: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Europe Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
  • Figure 10. Pre-Clinical ADME and Human Studies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. PK/PD Analysis and Reporting: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Dosing Simulations: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Risk Analysis: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Europe Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
  • Figure 16. Oncology: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Infectious Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Neurological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Autoimmune Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Gynecological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Cardiovascular Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Respiratory Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Europe Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
  • Figure 25. Pharmaceutical and Biotechnology Companies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Contract Research Organization: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Europe Pharmacokinetics Services Market - Revenue by Key Countries Revenue 2023 (US$ Million)
  • Figure 29. Europe Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 30. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 31. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 32. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 33. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 34. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 35. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)